World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
68324
World Ranking
8107
National Ranking
267

Overview

Luca Gianni is affiliated with Vita-Salute San Raffaele University in Italy. Their research primarily focuses on medical and biomedical fields, with a strong emphasis on oncology and cancer-related studies.

The main fields of study covered by their work include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these areas, they have contributed especially to the subfields of:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging
  • Molecular Biology

Their research addresses various topics, notably in cancer biology and treatment, including:

  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Breast Cancer Treatment Studies
  • Cancer Genomics and Diagnostics
  • Monoclonal and Polyclonal Antibodies Research

Their frequent co-authors include:

  • Giampaolo Bianchini
  • Pinuccia Valagussa
  • Claudio Zamagni
  • Giuseppe Viale
  • Matteo Dugo

Major venues where they have published multiple articles are:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • npj Breast Cancer
  • European Journal of Cancer

Some of their recent publications are:

  • "Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer", 2021, New England Journal of Medicine
  • "Treatment landscape of triple-negative breast cancer - expanded options, evolving needs", 2021, Nature Reviews Clinical Oncology
  • "Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial", 2020, The Lancet Oncology
  • "Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study", 2022, Annals of Oncology
  • "Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial", 2020, The Lancet Oncology

Best Publications

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

    Giorgio Minotti;Pierantonio Menna;Emanuela Salvatorelli;Gaetano Cairo

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

    Sunil Verma;David Miles;Luca Gianni;Ian E. Krop

  • Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

    Luca Gianni;Tadeusz Pienkowski;Young Hyuck Im;Laslo Roman

  • Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

    Giampaolo Bianchini;Justin M. Balko;Ingrid A. Mayer;Melinda E. Sanders

  • Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

    Luca Gianni;Wolfgang Eiermann;Vladimir Semiglazov;Alexey Manikhas

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Treatment of HER2-positive breast cancer: current status and future perspectives

    Carlos L. Arteaga;Mark X. Sliwkowski;C. Kent Osborne;Edith A. Perez

  • Triple-Negative Breast Cancer: An Unmet Medical Need

    Clifford A. Hudis;Luca Gianni

  • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

    David Cameron;Martine J Piccart-Gebhart;Richard D Gelber;Richard D Gelber;Marion Procter

  • Triple-negative breast cancer: disease entity or title of convenience?

    Lisa Carey;Eric Winer;Giuseppe Viale;David Cameron

  • Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

    J Baselga;D Rischin;M Ranson;H Calvert

  • HER2-positive breast cancer

    Sibylle Loibl;Luca Gianni

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

    José Baselga;Karen A. Gelmon;Shailendra Verma;Andrew Wardley

  • 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

    Luca Gianni;Tadeusz Pienkowski;Young Hyuck Im;Ling Ming Tseng

  • Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

    L Gianni;E Munzone;G Capri;F Fulfaro

  • European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

    E A Eisenhauer;W W ten Bokkel Huinink;K D Swenerton;L Gianni

  • Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

    L Gianni;C M Kearns;A Giani;G Capri

Frequent Co-Authors

Pinuccia Valagussa
Pinuccia Valagussa University of Louisville
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Michele Reni
Michele Reni Vita-Salute San Raffaele University
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
Véronique Diéras
Véronique Diéras Institute Curie
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation
Massimo Falconi
Massimo Falconi Vita-Salute San Raffaele University
Claudio Doglioni
Claudio Doglioni Vita-Salute San Raffaele University
Giampaolo Merlini
Giampaolo Merlini University of Pavia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

In addition to traditional medical programs, students interested in healthcare careers can explore a growing number of online degree options. For those seeking a fast entry into patient care, accelerated lpn programs online enable learners to become Licensed Practical Nurses in less time than traditional pathways.

For nurses aiming to specialize further, advancing from msn to pmhnp online programs can provide clinical expertise in psychiatric and mental health nursing, opening doors to in-demand roles. These pathways blend clinical experience with coursework and offer flexible schedules suited to working professionals.

If your passion leans towards healthcare leadership and management, consider an online master of health administration program. Many of these programs are both accessible and cost-effective. Prospective students should also explore the most affordable online mha programs to balance quality education with career goals and financial considerations.

Whether you are entering direct patient care or healthcare management, these online degree options offer flexibility and new pathways to rewarding careers in medicine.

Best Scientists Citing Luca Gianni

Trending Scientists

Recently Published Articles